Aspreva Pharmaceuticals Corporation

We are a team of highly motivated, talented and passionate individuals who share the vision of changing the treatment landscape for patients living with a less common disease. Aspreva's vision Aspreva's vision is to change the treatment landscape for people living with less common diseases by increasing the pool of evidence-based medicines available for these patients. What we do Aspreva is focused on addressing the needs of individuals with less common diseases through the identification, development and commercialization of existing medicines for new indications. Aspreva uses a proprietary screening program to identify late stage and approved medicines that show potential for high therapeutic impact in less common diseases. We then partner with pharmaceutical and biopharmaceutical companies to acquire the rights to develop the drug in these new indications, including clinical research and regulatory approvals. Once approved, we apply a strategic and specialized approach to commercializing products for these complex therapeutic categories. Our expertise lies in the clinical, regulatory and commercial development of products for complex diseases and specialized patient populations which differs significantly from traditional pharmaceutical activities. Aspreva is a leader in this new era of pharmaceutical partnering. For more information about our partnerships, please visit the Partners page. For information on our current research, please visit Clinical Trials. Why we do it Aspreva is driven by a desire to enrich the lives of millions of patients worldwide who are affected by less common diseases. We believe we can make a valuable contribution to the management of these diseases by delivering effective, evidence-based treatments. Our partnering strategy enables pharmaceutical and biopharmaceutical companies to develop their drugs, clinically and commercially outside of their products' strategic focus. It is the strength of our partnerships that deliver real benefit to our patients.

Contact Details: #1203,4464 Markham Street Victoria V8Z7X8 Canada Tel: 1 250 744-2488 Fax: 1 250 744-2498 Email: info@aspreva.com WWW: www.aspreva.com/

Loading...

Recent Publications by Aspreva Pharmaceuticals Corporation:
Mycophenolate mofetil as induction and maintenance therapy for lupus nephritis: rationale and protocol for the randomized, controlled Aspreva Lupus Management Study (ALMS). The Phase III Aspreva Lupus Management Study (ALMS) will investigate...	2nd April, 2008	Aspreva Pharmaceuticals Corp, Victoria, BC, Canada.	Lupus. 2007;16(12):972-80. DOI Direct Link

Press Releases on Aspreva Pharmaceuticals Corporation:
Follica Appoints Drug Development and Dermatology Veteran, William D. Ju, as Chief Executive Officer	13th May, 2009	Follica Inc.	BOSTON, May 13 /PRNewswire/ -- Follica Inc., a privately held developer of novel therapies for androgenetic alopecia and other hair follicle and skin disorders, today announced that William D. Ju, M.D
Satori Pharmaceuticals Raises $22M; Names Former Senior Pfizer Executive as CEO	8th January, 2009	Satori Pharmaceuticals Incorporated	CAMBRIDGE, Mass., Jan. 8 /PRNewswire/ -- Satori Pharmaceuticals Incorporated, a privately held developer of therapeutics for Alzheimer's disease, Parkinson's disease, and other
Follica Announces $11M in New Financing and Expanded Team	12th August, 2008	Follica Inc.	BOSTON, Aug. 12 /PRNewswire/ -- Follica Inc., a privately held developer of novel therapies for androgenetic alopecia and other hair follicle disorders, today announced an $11 million Series B

Aspreva Pharmaceuticals Corporation Clinical Trials:
Safety and Efficacy of Cellcept and Avonex as Combination Treatment in Multiple Sclerosis

Aspreva Pharmaceuticals Corporation (ASPV) Financial information Links from Barchart
ASPV Quote from from Barchart.com
ASPV Chart from from Barchart.com
ASPV Profile from from Barchart.com
ASPV Opinion from from Barchart.com
→View more Aspreva Pharmaceuticals Corporation finance information.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 557 times since April 2007, the link to the organisation's website has been followed 75 times

Recent Search Terms used to find this page: ADDRESS SEARCH FOR 972 744-2498 | aspreva pharmaceuticals corporation | clinical Study Manager at Aspreva Pharmaceuticals | Myogen | aspreva pharmaceuticals corporation | aspreva ltd contact telephone number | Aspreva Pharmaceuticals Inc. Contact | aspreva pharmaceuticals | Aspreva Pharmaceuticals 2009 | .

Search for more companies in Victoria

Search for more companies in

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for Aspreva Pharmaceuticals Corporation